News FDA knocks back Pharming's bid for wider Joenja use The FDA has turned down Pharming's bid to broaden the label of Joenja for rare immunodeficiency disorder APDS so it can be used in younger patients.
News First drug for rare disease APDS cleared for NHS use Pharming's Joenja has become the first disease-modifying drug that can be used by the NHS to treat APDS, an ultra-rare immunodeficiency disorder.
News Novartis buys Pharming priority review voucher for a song Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate.
News Pharming brings first drug for rare disease APDS to US Joenja will launch in April and could make upwards of $200m a year in sales, say analysts.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.